|
⚲
|
| Keyboard |
| Redmile Group LLC | |
|---|---|
| Firm | Redmile Group LLC |
| Address | Letterman Digital Arts Center One Letterman Drive, Suite D3300 San Francisco, CA 94129 |
| Source |
| Associated Funds | Form D | Role | 2011 - 2026 | Raised | AUM |
|---|---|---|---|---|---|
| Redmile Group LLC | |||||
| Redmile Growth Investments I LP | 021-408032 | Executive Officer | 122.0 M | 137.0 M | |
| Redco II Master Fund LP | 021-400720 | Executive Officer | 31.4 M | 1,555.9 M | |
| Redmile Biopharma Investments III LP | 021-385117 | Executive Officer | 500.2 M | 1,133.8 M | |
| Redco I LP | 021-367674 | Executive Officer | 187.5 M | 40.6 M | |
| Redmile Biopharma Investments II LP | 021-335974 | Executive Officer | 675.4 M of 675.4 M |
661.0 M | |
| Redmile Biopharma Investments I LP | 021-244604 | Promoter | 218.3 M of 218.3 M |
144.9 M | |
| Redmile Private Investments II LP | 021-231261 | Promoter | 131.2 M of 131.2 M |
7.0 M | |
| Redmile Private Investments I Affiliates LP | 021-281656 | Promoter | 28.7 M of 28.7 M |
3.5 M | |
| Redmile Special Opportunities Fund Ltd | 021-134870 | Director | 431.5 M | 58.5 M | |
| Redco II Offshore Fund LP | 021-400723 | Executive Officer | 579.0 M | ||
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
ADC Therapeutics SA ADCT
Pre-Funded Warrants · derivative
|
2025-10-27 | Buy | 3,846,153 | $3.90 | 14,999,997 |
|
ADC Therapeutics SA ADCT
Pre-Funded Warrants · derivative
|
2025-10-27 | Buy | 3,846,153 | $3.90 | 14,999,997 |
|
IGM Biosciences Inc IGMS
Non-Voting Common Stock · derivative
|
2025-08-14 | Disposed to issuer | 7,199,325 | ||
|
IGM Biosciences Inc IGMS
Pre-Funded Warrants to Purchase Common Stock · derivative
|
2025-08-14 | Disposed to issuer | 667,666 | ||
|
IGM Biosciences Inc IGMS
Common Stock
|
2025-08-14 | Disposed to issuer | 2,964,843 | ||
|
Shattuck Labs Inc STTK
Stock Option (Right to Buy) · derivative
|
2025-07-14 | Grant | 33,150 | $0.00 | |
|
IGM Biosciences Inc IGMS
Common Stock
|
2025-06-30 | Grant | 828 | $0.00 | |
|
ADC Therapeutics SA ADCT
Pre-Funded Warrants · derivative
|
2025-06-11 | Buy | 15,734,267 | $3.43 | 53,968,536 |
|
ADC Therapeutics SA ADCT
Pre-Funded Warrants · derivative
|
2025-06-11 | Buy | 12,465,234 | $3.43 | 42,755,753 |
|
Fate Therapeutics Inc FATE
Stock Option (Right to Buy) · derivative
|
2025-05-29 | Grant | 55,000 | $0.00 | |
|
IGM Biosciences Inc IGMS
Common Stock
|
2025-03-31 | Grant | 828 | $0.00 | |
|
IGM Biosciences Inc IGMS
Common Stock
|
2024-12-31 | Grant | 1,734 | $0.00 | |
|
Fate Therapeutics Inc FATE
Common Stock
|
2024-12-20 | Other | 1,084,936 | $1.68 | 1,822,692 |
|
Fate Therapeutics Inc FATE
Class A Convertible Preferred Stock · derivative
|
2024-12-20 | Other | 116,261 | $8.40 | 976,592 |
|
Fate Therapeutics Inc FATE
Common Stock
|
2024-12-20 | Buy | 397,964 | $1.68 | 668,580 |
|
Fate Therapeutics Inc FATE
Cash-settled Swaps · derivative
|
2024-12-20 | Other | 56,331 | $1.68 | 94,636 |
|
Fate Therapeutics Inc FATE
Class A Convertible Preferred Stock · derivative
|
2024-12-20 | Other | 116,261 | $8.40 | 976,592 |
|
Fate Therapeutics Inc FATE
Common Stock
|
2024-12-20 | Other | 1,084,936 | $1.68 | 1,822,692 |
|
Fate Therapeutics Inc FATE
Common Stock
|
2024-12-20 | Sell | 341,633 | $1.68 | 573,943 |
|
Fate Therapeutics Inc FATE
Class A Convertible Preferred Stock · derivative
|
2024-12-12 | Conversion | 6,022 | ||
| showing 20 of 200 most recent transactions | |||||